All In Biotech

Drug Trial Radar · NCT04240158

IW-6463 Safety Study in Healthy Elderly Subjects

Evaluating the Safety, Tolerability, and Pharmacodynamic Properties of IW-6463 in Healthy Elderly Subjects

Last checked: Nov 19, 2026Latest source record: Aug 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

24

Actual

Start

Jan 6, 2020

Primary completion

May 22, 2020

Study completion May 22, 2020

Sponsor

Lead sponsor
Tisento TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, 2-way cross-over study in healthy male and female elderly participants.

Conditions

  • Other

Interventions

  • IW-6463Drug

    IW-6463 Tablet

  • Matching PlaceboDrug

    Matching Placebo Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Cerebral Blood Flow (CBF) at Day 15Time frame: Baseline, 15 days
  2. Number of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 42 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Human Drug Research (CHDR)

    Leiden, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.